-+ 0.00%
-+ 0.00%
-+ 0.00%

Lexaria says US$7.9 million funding boost extends cash runway through 2027

PUBT·09/17/2026 13:11:21
Listen to the news
Lexaria says US$7.9 million funding boost extends cash runway through 2027
  • Lexaria Bioscience issued a response citing “aggressive” trading activity as the main driver of recent share-price pressure.
  • Net proceeds of USD 7.9 million from an Australian tax refund and warrant exercise lifted cash to about USD 4.60 per share.
  • Financing was priced at USD 12.92 per share; shares outstanding total 2,100,000.
  • Management expects the added cash to fund operations through 2027; no additional equity or debt financings planned in 2026.
  • Business development talks are expected to reduce Lexaria-funded R&D spending in 2027 by shifting costs to partners.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexaria Bioscience Corp. published the original content used to generate this news brief via TheNewswire (Ref. ID: 202609170910TNWSWRCACNPR_____1AqRFbZm6) on September 17, 2026, and is solely responsible for the information contained therein.